Quick Answer
Vaxart, Inc. reported Operating Income Loss of $18.07 million for the year ending 2025.
- Vaxart, Inc. showed an increase of +127.3% in Operating Income Loss from 2024 to 2025.
- This data is from Vaxart, Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2009 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 19 years of available data (2009 to 2025), Vaxart, Inc.'s Operating Income Loss has grown by 200.5%.
- Historical annual values: Fiscal year 2025: $18.07 million | Fiscal year 2024: -$66.29 million | Fiscal year 2023: -$83.35 million | Fiscal year 2022: -$114.59 million | Fiscal year 2021: -$72.75 million | Fiscal year 2020: -$30.17 million | Fiscal year 2019: -$15.79 million | Fiscal year 2018: -$21.76 million | Fiscal year 2017: -$10.02 million | Fiscal year 2017: -$27.50 million | Fiscal year 2016: -$25.20 million | Fiscal year 2015: -$19.50 million | Fiscal year 2014: -$11.50 million | Fiscal year 2013: -$22.10 million | Fiscal year 2012: -$22.90 million | Fiscal year 2011: -$9.76 million | Fiscal year 2011: -$30.50 million | Fiscal year 2010: -$1.20 million | Fiscal year 2009: -$17.98 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: